# A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

> **NCT06168409** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 218 (actual)

## Conditions studied

- Resistant Hypertension

## Interventions

- **DRUG:** Baxdrostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06168409
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2025-08-17
- **Final completion:** 2025-08-17
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168409, "A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06168409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*